US Neurotechnology Market Research Report Forecast to 2040

Neurotechnology is a broad term that encompasses any technology that interfaces with the nervous system to monitor or modulate neural activity. This can be done for a variety of purposes, including research, diagnosis & treatment, and enhancement. Furthermore, neurotechnologies can be invasive or non-invasive. Invasive neurotechnologies require the implantation of electrodes or other devices into the brain or nervous system. Non-invasive neurotechnologies do not require implantation, such as electroencephalography (EEG) and functional magnetic resonance imaging (fMRI).

The US neurotechnology market is predicted to expand due to growing incidence of neurological disorders and increasing number of geriatric populations, and rapid advancements in technology, However, cost of development and implementation are limiting market expansion. Personalized medicine, on the other hand, boosts the market's attractiveness. Another aspect driving market expansion is the increasing government investment in healthcare infrastructures.

Market Segmentation

Based on the technology, the market has been segmented into neurosensing, neurostimulation, neuroprosthese and neurorehabilitation.

Based on the indication, the market has been segmented into cognitive disorders, pain treatment, epilepsy, Parkinson's disease, depression, and others.

Based on test type, US neurotechnology market has been segmented into hospitals & clinics, ambulatory surgical centers, academic & research laboratories, specialty clinics, and homecare.

Major Players

The key market players in the US Neurotechnology market are Medtronic, Boston Scientific Corporation, Abbott Laboratories, Inc., Cochlear Ltd., Shimadzu Corporation, and Neuronetics

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
- 3.7.1 Data forecasting Technique
3.8 DATA MODELING
- 3.8.1 microeconomic factor analysis:
- 3.8.2 Data modeling:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 Growing Incidence of Neurological Disorders
- 4.2.2 increasing number of geriatric population
- 4.2.3 Rapid advancements in technology
4.3 RESTRAINTS
- 4.3.1 Cost of Development and Implementation
4.4 OPPORTUNITY
- 4.4.1 Personalized Medicine creating promising opportunity for neurotechnology Market

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 Manufacturing
- 5.1.3 Distribution And Sales
- 5.1.4 Post-Sales Monitoring
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 Threat of New Entrants
- 5.2.2 Bargaining Power of Suppliers
- 5.2.3 Threat of Substitutes
- 5.2.4 Bargaining Power of Buyers
- 5.2.5 Intensity of Rivalry
5.3 IMPACT OF COVID-19 ON THE US NEUROTECHNOLOGY MARKET
- 5.3.1 impact on supply chain
- 5.3.2 IMPACT ON KEY PLAYERS

6 US NEUROTECHNOLOGY MARKET, BY TECHNOLOGY

6.1 OVERVIEW

7 US NEUROTECHNOLOGY MARKET, BY INDICATION

7.1 OVERVIEW

8 US NEUROTECHNOLOGY MARKET, BY END USER

8.1 OVERVIEW

9 COMPETITIVE LANDSCAPE

9.1 INTRODUCTION
9.2 MARKET SHARE ANALYSIS, 2022
9.3 COMPETITOR DASHBOARD
9.4 PUBLIC PLAYERS STOCK SUMMARY
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
- 9.6.2 Partnership/Investment/Collaboration

10 COMPANY PROFILES

10.1 MEDTRONIC
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 FINANCIAL OVERVIEW
- 10.1.3 PRODUCTS OFFERED
- 10.1.4 KEY DEVELOPMENTS
- 10.1.5 SWOT ANALYSIS
- 10.1.6 KEY STRATEGIES
10.2 BOSTON SCIENTIFIC CORPORATION
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 FINANCIAL OVERVIEW
- 10.2.3 PRODUCTS OFFERED
- 10.2.4 KEY DEVELOPMENTS
- 10.2.5 SWOT ANALYSIS
- 10.2.6 KEY STRATEGIES
10.3 NEURONETICS
- 10.3.1 COMPANY OVERVIEW
- 10.3.2 FINANCIAL OVERVIEW
- 10.3.3 PRODUCTS OFFERED
- 10.3.4 KEY DEVELOPMENTS
- 10.3.5 KEY STRATEGIES
10.4 MINDMAZE
- 10.4.1 COMPANY OVERVIEW
- 10.4.2 FINANCIAL OVERVIEW
- 10.4.3 Products OFFERed
- 10.4.4 KEY DEVELOPMENTS
- 10.4.5 Key Strategy
10.5 SHIMADZU CORPORATION
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 FINANCIAL OVERVIEW
- 10.5.3 Products OFFERed
- 10.5.4 KEY DEVELOPMENTS
- 10.5.5 SWOT ANALYSIS
- 10.5.6 Key Strategy
10.6 ABBOTT LABORATORIES, INC.
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 FINANCIAL OVERVIEW
- 10.6.3 PRODUCTS OFFERED
- 10.6.4 KEY DEVELOPMENTS
- 10.6.5 KEY DEVELOPMENTS
- 10.6.6 SWOT ANALYSIS
- 10.6.7 KEY STRATEGIES
10.7 COCHLEAR LTD.
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 FINANCIAL OVERVIEW
- 10.7.3 PRODUCTS OFFERED
- 10.7.4 Key developments
- 10.7.5 SWOT ANALYSIS
- 10.7.6 KEY STRATEGIES
10.8 SYNCHRON
- 10.8.1 COMPANY OVERVIEW
- 10.8.2 FINANCIAL OVERVIEW
- 10.8.3 PRODUCTS OFFERED
- 10.8.4 KEY DEVELOPMENTS
- 10.8.5 KEY STRATEGIES
10.9 NEOFECT
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 FINANCIAL OVERVIEW
- 10.9.3 PRODUCTS OFFERED
- 10.9.4 KEY DEVELOPMENTS
- 10.9.5 KEY STRATEGIES
10.10 REHABTRONICS INC
- 10.10.1 COMPANY OVERVIEW
- 10.10.2 INANCIAL OVERVIEW
- 10.10.3 PRODUCTS OFFERED
- 10.10.4 KEY DEVELOPMENTS
- 10.10.5 KEY STRATEGIES

11 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 30
TABLE 2 US NEUROTECHNOLOGY MARKET, BY TECHNOLOGY, 2019-2040 (USD MILLION) 48
TABLE 3 US NEUROTECHNOLOGY MARKET, BY INDICATION, 2019-2040 (USD MILLION) 50
TABLE 4 US NEUROTECHNOLOGY MARKET, BY END USER, 2019-2040 (USD MILLION) 52
TABLE 5 PUBLIC PLAYERS STOCK SUMMARY 56
TABLE 6 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL 56
TABLE 7 PRODUCT LAUNCH/PRODUCT APPROVAL 57
TABLE 8 PARTNERSHIP/INVESTMENT/COLLABORATION 58
TABLE 9 MEDTRONIC: PRODUCTS OFFERED 60
TABLE 10 MEDTRONIC: KEY DEVELOPMENTS 61
TABLE 11 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 65
TABLE 12 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENTS 65
TABLE 13 NEURONETICS: PRODCUTS OFFERED 68
TABLE 14 MINDMAZE: PRODCUTS OFFERED 70
TABLE 15 MINDMAZE: KEY DEVELOPMENTS 71
TABLE 16 SHIMADZU CORPORATION: PRODUCTS OFFERED 73
TABLE 17 ABBOTT LABORATORIES, INC. : PRODUCTS OFFERED 77
TABLE 18 ABBOTT LABORATORIES, INC.: KEY DEVELOPMENTS 77
TABLE 19 COCHLEAR LTD.: PRODUCTS OFFERED 81
TABLE 20 COCHLEAR LTD.: KEY DEVELOPMENTS 81
TABLE 21 SYNCHRON: PRODUCTS OFFERED 84
TABLE 22 SYNCHRON: KEY DEVELOPMENTS 84
TABLE 23 NEOFECT: PRODCUTS OFFERED 86
TABLE 24 REHABTRONICS INC: PRODCUTS OFFERED 88
TABLE 25 REHABTRONICS INC: KEY DEVELOPMENTS 88

LIST OF FIGURES

FIGURE 1 US NEUROTECHNOLOGY MARKET: STRUCTURE 17
FIGURE 2 US NEUROTECHNOLOGY MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032) 34
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2040) 37
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2040) 38
FIGURE 5 VALUE CHAIN ANALYSIS OF THE US NEUROTECHNOLOGY MARKET 40
FIGURE 6 PORTER'S FIVE FORCES ANALYSIS: US NEUROTECHNOLOGY MARKET 43
FIGURE 7 US NEUROTECHNOLOGY MARKET, TECHNOLOGY SEGMENT ATTRACTIVENESS, 2022 & 2040 (USD MILLION) 47
FIGURE 8 US NEUROTECHNOLOGY MARKET, BY TECHNOLOGY, 2022 & 2040 (USD MILLION) 47
FIGURE 9 US NEUROTECHNOLOGY MARKET SHARE (%), BY TECHNOLOGY, 2022 48
FIGURE 10 US NEUROTECHNOLOGY MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2022 & 2040 (USD MILLION) 49
FIGURE 11 US NEUROTECHNOLOGY MARKET, BY INDICATION, 2022 & 2040 (USD MILLION) 50
FIGURE 12 US NEUROTECHNOLOGY MARKET SHARE (%), BY INDICATION, 2022 50
FIGURE 13 US NEUROTECHNOLOGY MARKET, END USER SEGMENT ATTRACTIVENESS, 2022 & 2040 (USD MILLION) 51
FIGURE 14 US NEUROTECHNOLOGY MARKET, BY END USER, 2022 & 2040 (USD MILLION) 52
FIGURE 15 US NEUROTECHNOLOGY MARKET SHARE (%), BY END USER, 2022 52
FIGURE 16 US NEUROTECHNOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2022 54
FIGURE 17 COMPETITOR DASHBOARD: US NEUROTECHNOLOGY MARKET 55
FIGURE 18 MEDTRONIC: FINANCIAL OVERVIEW SNAPSHOT 60
FIGURE 19 MEDTRONIC: SWOT ANALYSIS 61
FIGURE 20 BOSTON SCIENTIFIC CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 64
FIGURE 21 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS 66
FIGURE 22 NEURONETICS: FINANCIAL OVERVIEW SNAPSHOT 68
FIGURE 23 SHIMADZU CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 73
FIGURE 24 SHIMADZU CORPORATION: SWOT ANALYSIS 74
FIGURE 25 ABBOTT LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 76
FIGURE 26 ABBOTT LABORATORIES, INC. : SWOT ANALYSIS 78
FIGURE 27 COCHLEAR LTD.: FINANCIAL OVERVIEW SNAPSHOT 80
FIGURE 28 COCHLEAR LTD.: SWOT ANALYSIS 82